key: cord-0804620-edlog09r
authors: Kim, D.; Pekgun, P.; Yildirim, I.; Keskinocak, P.
title: Resource Allocation for Different Types of Vaccines against COVID-19: Tradeoffs and Synergies between Efficacy and Reach
date: 2021-02-01
journal: nan
DOI: 10.1101/2021.01.28.21250713
sha: fc72b53f7c4bf0b22dfd145ca9c908d81ac61b04
doc_id: 804620
cord_uid: edlog09r

Objective: During the COVID-19 pandemic, multiple vaccine candidates were developed in record time. The primary decision for a vaccine-ordering decision-maker then becomes how to allocate limited resources between different types of vaccines. One may expect that available resources should be favored towards a vaccine with high efficacy if it can be distributed as widely as any other vaccine. However, if a high efficacy vaccine consumes more resources than a vaccine with lower efficacy due to distributional challenges, the decision is no longer trivial as a widespread vaccination is necessary to reach herd immunity. Methods: We adapt a Susceptible-Infected-Recovered-Deceased (SIR-D) model with vaccination and simulate the level of infection attack rate (IAR) under different resource consumption ratios between two vaccine types with different resource allocation decisions. Results: We find that when there are limited resources, allocating resources entirely to a vaccine with high efficacy that becomes available earlier than a vaccine with lower efficacy that becomes available later does not always lead to a lower IAR, particularly if the former can immunize less than a range of 5.9% to 6.4% of the population (with the selected study parameters) before the latter becomes available. Sensitivity analyses show that this result stays robust under different efficacy levels for the higher efficacy vaccine. Conclusions: Our results show that the reach of a vaccine to be distributed widely under limited resources is a key factor to achieve low IAR levels, even though the vaccine may be of higher efficacy and may become available earlier than others. Manufacturing a novel vaccine lacking a fully developed suitable infrastructure for its effective distribution and storage may impact the potential benefits of the immunization program. Understanding the tradeoffs between efficacy and reach is critical for resource allocation decisions between different vaccine types to maximize the improvement in health outcomes.

Objective: During the COVID-19 pandemic, multiple vaccine candidates were developed in 2 record time. The primary decision for a vaccine-ordering decision-maker then becomes how to 3 allocate limited resources between different types of vaccines. One may expect that available 4 resources should be favored towards a vaccine with high efficacy if it can be distributed as 5

widely as any other vaccine. However, if a high efficacy vaccine consumes more resources than 6 a vaccine with lower efficacy due to distributional challenges, the decision is no longer trivial as 7 a widespread vaccination is necessary to reach herd immunity. 8 9

Methods: We adapt a Susceptible-Infected-Recovered-Deceased (SIR-D) model with vaccination 10 and simulate the level of infection attack rate (IAR) under different resource consumption ratios 11 between two vaccine types with different resource allocation decisions. 12 13

Results: We find that when there are limited resources, allocating resources entirely to a vaccine 14 with high efficacy that becomes available earlier than a vaccine with lower efficacy that becomes 15 available later does not always lead to a lower IAR, particularly if the former can immunize less 16 than a range of 5.9% to 6.4% of the population (with the selected study parameters) before the 17 latter becomes available. Sensitivity analyses show that this result stays robust under different 18 efficacy levels for the higher efficacy vaccine.

Conclusions: Our results show that the reach of a vaccine to be distributed widely under limited 21

resources is a key factor to achieve low IAR levels, even though the vaccine may be of higher 22

efficacy and may become available earlier than others. Manufacturing a novel vaccine lacking a 23

fully developed suitable infrastructure for its effective distribution and storage may impact the 24 potential benefits of the immunization program. Understanding the tradeoffs between efficacy 25 and reach is critical for resource allocation decisions between different vaccine types to 26 maximize the improvement in health outcomes. 27 of January 2021. The chief adviser to Operation Warp Speed (OWS) also stated that Johnson & 25 Johnson could have enough data to seek for EUA from FDA in January 2021 [8] . 26

Despite the high efficacies, mRNA-based COVID-19 vaccine candidates may face 27 critical supply-chain challenges from distribution to storage since they require cold temperatures 28 to maintain their aptness. For instance, Pfizer & BioNTech and Moderna's vaccines need to be 29 stored at about minus 70 Celsius degrees and minus 20 Celsius degrees, respectively [9] . 30

Advanced cold-chain logistics and storage solutions are not available in many regions, which can 31 impede mass vaccine distribution efforts while maintaining quality. On the other hand, 32

adenovirus-vector COVID-19 vaccine candidates, despite their lower efficacy than mRNA-based 33 vaccines, can be stored at 2-8 Celsius degrees, which is the temperature seasonal flu vaccine 34 requires, and therefore, their mass distribution is expected to be easier [9, 10] . The reach of a 35 vaccine, the ability to distribute it widely, which can be impeded by supply-chain challenges, can 36 impact vaccine coverage and the proportion of the population who have access to the vaccine 37 jeopardizing infection control and achievement of herd immunity through vaccination. 38

Having an efficacious vaccine approved for use will be of little use if not enough people 39

can have access to the vaccine. Both having the efficacious vaccine and having a high 40 vaccination coverage will be essential. With these insights, governments, vaccine manufacturers 41 and researchers have been working on developing effective COVID-19 vaccine ordering and 42 distribution strategies. Specifically, vaccine prioritization-which group of people should be 43 prioritized for vaccination-has gained notable attention [11] . However, there has not been 44 enough attention on which vaccine, among different candidates, should be prioritized for 45 ordering and administering, which would have an implication on the allocation of limited 46 available resources. Considering the high efficacy of mRNA-based vaccines and lower efficacy 47 of other types of vaccines, should a vaccine-ordering decision maker always favor an mRNA-48 based vaccine despite its potential logistics and storage challenges? Or should lower efficacy 49 vaccines, which can be distributed widely using existing vaccine logistics and storage 50 infrastructure, be favored? 51

The main goal of this study is to understand how to allocate limited resources between 52 different types of vaccines considering the tradeoffs and synergies between efficacy vs. reach. 53

Specifically, we seek to answer the following question: "Is it worth ordering a vaccine with low-54 efficacy that becomes available later if it can be distributed more widely than a vaccine with 55 high-efficacy that becomes available sooner but consumes more resources for distribution or 56 storage?" Using a modified Susceptible-Infected-Recovered-Deceased (SIR-D) model, we 57 simulate the health outcomes, infection attack rate (IAR) and the peak of daily infections (i.e., 58 the highest percentage of the population who get newly infected on a single day), under different 59 resource consumption ratios between two types of vaccines with different resource allocation 60 decisions. The results of this study are aimed to guide decision makers in vaccine ordering and 61 distribution with their resource planning decisions during a pandemic when multiple types of 62 vaccines become available. 63

We consider two types of vaccines that become available at different points of time. The 65 vaccine with high efficacy (denoted vaccine-H, hereafter) becomes available sooner than the 66 vaccine with lower efficacy (denoted vaccine-L, hereafter). We assume that both vaccine types 67 require a single dose and an individual who receives an effective vaccine of either type becomes 68 immunized immediately. In our model, there is a fixed and uniform number of resources (K) 69 available each day. We consider the resource allocation decision for each vaccine type (! ! , ! " ∈ 70 [0,1], ! ! + ! " = 1), assuming that it cannot be modified once it is committed. Thus, the resource 71 allocation decision directly defines the quantity of each vaccine type that could be administered 72 each day. We normalize the resource consumption requirements of each type of vaccine such 73 that for each unit of resource, while one person can receive one unit of vaccine-L, only a 74 "fraction of one person (*)" can receive one unit of vaccine-H. We denote this ratio as the 75 resource consumption ratio (* < 1), which indicates how widely vaccine-H can be distributed 76 relative to vaccine-L given limited available resources. We set a range of 0.1 to 0.7 for the 77 resource consumption ratio in our simulations. We present the daily quantity of each vaccine 78 type that can be administered as a function of the allocation decision and the resource 79 consumption ratio in Table 1 . 80 candidates. Note that if we were to assume that both vaccine types became available at the same 87 time, the decision would become trivial: choose the resource allocation such that the number of 88 immunized individuals on each day is maximized. Thus, we choose a non-trivial setting where 89 the high efficacy vaccine becomes available earlier; vaccine-H and vaccine-L become available 90 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.28.21250713 doi: medRxiv preprint on days 209 and 239 from the start of the pandemic, respectively. We also examine different 91 days of availability for vaccine-L, keeping that of vaccine-H on day 209, within the range of 239 92 to 259 in the sensitivity analyses reported in Supplemental Materials. We assume that during the 93 period when only vaccine-H is available (from day 209 to 238), any unused daily resources are 94

In addition to these key parameters of interest, we choose epidemiological parameter values, 96 fixed throughout the simulations, based on the SARS-CoV-2 characteristics. You et al. (2020) 97 report that the infectious period of COVID-19 is estimated to be an average of 13.96 days with a 98 standard deviation of 5.20 days [12] . Hence, we set the recovery rate of the disease to be 0.0716. 99

According to Johns Hopkins Coronavirus Research Center, the case fatality ratio (CFR), which is 100 the ratio of reported deaths to reported cases, is approximately 2% in the United States [13] . 101

Considering this, we set the death rate of the disease to be 0.0015, at which CFR is 102 approximately 2.04% in our simulations. Severity of a disease is often described by reproduction 103 number (, # ) by epidemiologists. The Centers for Disease and Prevention (CDC) has developed 104 COVID-19 Pandemic Planning Scenarios and suggested three different basic reproduction 105 numbers: 2.0, 2.5 and 4.0 [14] . We use the reproduction number of 2.0 due to a few reasons, 106 even though the reproduction number of 2.5 is recommended by the CDC as the best parameter 107 value. In particular, facing a pandemic with a highly infectious disease, such as in the case of 108 COVID-19, many non-pharmaceutical interventions, such as mask mandates and physical 109 distancing, are often implemented, which can contribute to a considerable decrease in the 110 reproduction number [15] . While we do not model such non-pharmaceutical interventions in our 111 simulations, we instead consider a lower reproduction number. In addition, we also compare the 112 number of daily infections and cumulative infections through day 208 (before the distribution of 113 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.28.21250713 doi: medRxiv preprint vaccine-H) in our simulations to the COVID-19 datasets from [16] , which estimate and forecast 114 the number of infected people including those who are not tested or confirmed. Assuming that 115 both vaccine types become available for distribution before the peak of daily infections, our 116 simulation results under a reproduction number of 2.0 are aligned with the estimates in these 117 public datasets. Thus, we conclude that a reproduction number of 2.0 is a more realistic choice 118 for our simulations. To set the reproduction number at 2.0, considering the recovery rate and 119 death rate, we set the disease-transmission rate to be 0.1462. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. We run the simulation using R software with a population size of 10.6 million (approximate 145 population of the state of Georgia [17]). We initialize the simulation such that 0.000001% of this 146 population is infected and the rest are susceptible on day 1. The decision maker initially acquires 147 the total supply of resources equivalent to the population size and plans to use the resources 148 uniformly over 180 days (i.e., daily resource / =10.6 million / 180). The simulation is run over 149 a one-year planning horizon with varying resource allocations between the two vaccine types 150 (! ! , ! " ; ! ! + ! " = 1) within the range of 0 to 1 with a discrete step size of 0.1, and varying 151 resource consumption ratios within the range of 0.1 to 0.7 with a discrete step size of 0.02. We 152 evaluate the impact of a resource allocation policy using IAR as the main health outcome. 153

Our simulations show that if no vaccines are introduced, approximately 79.84% of the 155 population is infected with the disease. In addition, about 1.29% of the population is newly 156 infected at the peak of the daily infections on day 249 from the start of the pandemic, while the 157 number of infected individuals is the highest on day 259 with 15.61% of the population infected. 158 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10. 1101 /2021 In the simulations with the vaccines, vaccine-H and vaccine-L are introduced on days 209 and 159 239, respectively, which is before the peak of daily infections. On day 208 (i.e., one day before 160 vaccine-H becomes available), the cumulative number of cases is at approximately 4.15% of the 161 population, of whom 2.03% actively spread the disease to the susceptible population. 162 Table 2 171 Table 3 shows the estimated IAR (rounded to four significant figures) under different 172 resource consumption ratios in the range of 0.34 to 0.4 with different resource allocation 173 decisions. 174 * Total daily immunized population varies depending on the resource consumption ratio . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; Figure 1 depicts the results in Table 3 on a two-dimensional graph with the allocation 175 decision as an independent variable and IAR as a dependent variable. Figure 2 presents the IAR 176 on a three-dimensional graph with varying resource consumption ratios and resource allocation 177 decisions. Figure 3 and Figure 4 present the number of daily infections and cumulative infections 178 with respect to the population over time, respectively. When the resource consumption ratio is at 179 most 0.34, allocating the resources entirely to vaccine-L (i.e., ! ! = 0, ! " = 1) minimizes IAR. 180

On the other hand, allocating the resources entirely to vaccine-H (i.e., ! ! = 1, ! " = 0) 181 minimizes IAR only when the resource consumption ratio is at least 0.4. When the resource 182 consumption ratio is between 0.34 and 0.4, one vaccine type is not favored entirely, and a 183 decision on how much to allocate the resources to each vaccine type needs to be made. 184 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.28.21250713 doi: medRxiv preprint and consumption ratios (*). When comparing two different resource consumption ratios that are 195

both less than or equal to 0.34 (i.e., * $ < * % ≤ 0.34), the one with * $ can achieve a smaller IAR 196 with a lower ! ! than the one with * % and a higher ! ! . 197 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.28.21250713 doi: medRxiv preprint IAR among the three scenarios is achieved when * = 0.4 and ! ! = 1, followed by when ! " = 1 207 and when * = 0.34 and ! ! = 1. 208 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.28.21250713 doi: medRxiv preprint

In this study, we simulate the trajectory of an infectious disease using a modified SIR-D 210 model when two types of vaccines with different efficacies and resource consumption rates were 211 introduced at different points in the horizon during a pandemic. We demonstrate that the reach of 212 a vaccine to be distributed widely under limited resources is a key factor to achieve low IAR 213 levels, even though the vaccine may be of higher efficacy and may become available earlier than 214 others. A recent study modeled a similar setting with various vaccine efficacies, daily 215 administered quantities, and reproduction numbers for the case of a single type of vaccine (either 216

prophylactic vaccine, disease-modifying vaccine, or a composite of the two); thus, resource 217 allocation decisions between multiple types of vaccines, as in our study, were not considered 218

[18]. The study showed that the wider reach of a vaccine could result in significant reductions in 219 total infections and deaths, which is consistent with our study's findings. However, we consider 220 two types of prophylactic vaccines-vaccine-H and vaccine-L-whose daily quantities whereas the adenovirus-vectored vaccines do not. Our study captures the impact of these 231 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.28.21250713 doi: medRxiv preprint challenges and thus, the reach of the vaccines through the resource consumption ratio parameter, 232 and shows that allocating more resources to vaccine-H that becomes available earlier than 233 vaccine-L does not always guarantee better health outcomes if vaccine-H cannot be distributed 234 more widely than vaccine-L. 235

Reducing the number of infections is of paramount importance during a pandemic, which is 236 possible via various non-pharmaceutical and pharmaceutical interventions, including 237 prophylactic vaccines. The decline in new infections can lead to a decline in the effective 238 reproduction number and, potentially, even the eradication of the pandemic. Hence, the 239 implementation of effective vaccines as early as possible is of the essence. In addition, the 240 number of individuals who can be vaccinated by either type of vaccine each day throughout the 241 epidemic (both before and after the peak of daily infections) critically affects the potential 242 benefits of a vaccine upon its implementation. One may intuitively expect that allocating 243 resources primarily towards vaccine-H, which becomes available sooner, can minimize IAR. 244

However, our simulations indicate that this may not always be true. In particular, allocating more 245 resources to vaccine-H, when it is highly resource-intensive, leads to fewer individuals being 246 vaccinated and a worse overall IAR. Even when vaccine-L becomes available after the peak of 247 daily infections, this continues to hold. 248

Accordingly, identifying what percent of the population can be immunized with vaccine-H 249 before vaccine-L becomes available plays a key role in the resource allocation decision between 250 the two types of vaccines. Since we assume that the resource allocation decisions are made 251 before either vaccine type is introduced with fixed epidemiological parameter values and vaccine 252 attributes, as shown in Table 2 , the allocation decisions can aim to either 1) immunize more 253 people early on with vaccine-H in lieu of utilizing larger quantities of vaccine-L once it becomes 254 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.28.21250713 doi: medRxiv preprint available, or 2) immunize fewer people early on with vaccine-H and more people later utilizing a 255 larger quantity of vaccine-L once it becomes available. If the first strategy is chosen, the decision 256 maker needs to increase the resource allocation to vaccine-H, and if the second strategy is 257 chosen, the opposite action needs to be taken. The tradeoff is that in the first strategy where more 258 resources are allocated to the resource-intensive but effective vaccine-H, more people can be 259 vaccinated with vaccine-H before vaccine-L becomes available (days 209-238). However, since 260 the allocation decision is made at the beginning of the horizon and cannot be modified 261 afterwards, this then implies fewer resources allocated to the less resource-intensive vaccine-L, 262 which can reach a wider population. The result is that not many people can be vaccinated with 263 vaccine-L once it becomes available (days 239-365), as compared to the second strategy where 264 more resources are allocated to vaccine-L from the beginning. Thus, in order for the first strategy 265 to be preferable from a health outcome perspective, vaccine-H should be able to immunize a 266 sufficient number of people early on (days 209-238) to exceed the health benefits from a larger 267 vaccine coverage in later periods (days 239-365) using the second strategy. Our results show that 268 if the resource consumption ratio is at least 0.4 and, consequently, at least 6% of the population 269 can be immunized with vaccine-H before vaccine-L becomes available, then the first strategy is 270 preferred, and vaccine-H should be fully allocated all available resources (i.e., ! ! = 1). This 271 observation is driven by the fact that a sufficient number of individuals need to be immunized 272 before the peak of daily infections is reached so that fewer people become infected and spread 273 the disease. When we examine the number of daily infections in our simulations, the case of 274 ! ! = 1 lowers the peak of daily infections if the resource consumption ratio is at least 0.16, 275 which is a lot lower than the 0.4 threshold for this case to hold. On the other hand, if at most 276 5.1% of the population could be immunized with vaccine-H before vaccine-L becomes available 277 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.28.21250713 doi: medRxiv preprint (which occurs when the resource consumption ratio is at most 0.34, i.e., vaccine-H is highly 278 resource-intensive), then the second strategy is preferred and vaccine-L should be fully allocated 279 all available resources (i.e., ! " = 1). As shown in Figure 3 and Figure 4 , even though the peak of 280 daily infections is higher when ! " = 1 compared to the peak when * = 0.34 and ! ! = 1, the 281 former peak occurs only a day before the latter peak, and the number of daily infections drops 282 faster when ! " = 1, which leads overall to a lower IAR. These results remain robust under 283 different efficacy levels of vaccine-H from 85% to 95% and different days of availability for 284 vaccine-L from 239 to 259, as shown in Supplemental Materials, despite different resource 285 consumption ratio thresholds based on the efficacy of vaccine-H and the availability day for 286 vaccine-L, respectively. The different resource consumption ratio thresholds in Supplemental 287

it can immunize less than a range of 5.9% to 6.4% of the population before vaccine-L becomes 289

Our study also shows that an incorrect resource allocation, or a resource allocation that 291 neglects the extent of resource consumption differences between the two vaccine types, can have 292 a major impact on the total number of infections. When vaccine-H is highly resource-intensive 293 (the resource consumption ratio is at most 0.34), a linear increase in the allocated resources to 294 vaccine-H results in an increase in the IAR at a faster rate. For example, when the resource 295 consumption ratio is exactly 0.34, the IAR under ! " = 1 is about 1.22% lower than the IAR 296 under ! ! = 1. For a total population size of 10.6 million as in our model, this corresponds to 297 approximately 130,000 infections that could have been averted by allocating all resources to 298 vaccine-L. As the resource consumption ratio declines and vaccine-H becomes even more 299 resource-intensive than vaccine-L, the impact on IAR can even be more drastic, with differences 300 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10. 1101 /2021 in IAR due to the two allocation policies increasing at a faster rate. For example, when the 301 resource consumption ratio is 0.24, the difference in IAR is 5.44%, while when the ratio further 302 declines to 0.14, the difference in IAR increases to 9.85%, corresponding to an increase from 303 about 570,000 infections to 1.04 million infections that could have been averted by allocating all 304 resources to the lower-efficacy but less resource-intensive vaccine-L. On the other hand, when 305 the resource consumption ratio is at least 0.4, a linear increase in the allocation of resources to 306 vaccine-H results in a lower IAR at a faster rate. For example, when the resource consumption 307 ratio is 0.4, 0.5 and 0.6, the IAR under ! ! = 1 is 1.20%, 5.07% and 8.71% lower than the IAR 308 under ! " = 1, respectively. Thus, when vaccine-H is not as highly resource-intensive, allocation 309 of resources towards the high efficacy vaccine which becomes available earlier can lead to lower 310

The resource and resource consumption can be interpreted in many ways depending on the 312 context. For instance, the resource could correspond to trained healthcare workers, where each 313 vaccine administration site needs to identify how many trained health-care workers are required 314 to administer vaccine-H if it requires more stringent quality monitoring and administration 315 processes than vaccine-L. Alternatively, the resource may refer to a fixed monetary budget, 316

where the resource consumption ratio would imply differences in the cost of production, 317 distribution, storage or deployment of vaccine-H relative to that of vaccine-L. For instance, in 318

September 2020, the U.S. Department of Health and Human Services (HHS) and the CDC 319 provided $200 million to jurisdictions for COVID-19 vaccine preparedness, which could be used 320 to support vaccine providers and healthcare workforce, open new vaccine administration sites 321 and purchase personal protective equipment [19] . A third alternative interpretation for resource 322 could be related to storage requirements. An administration site needs to determine how much of 323 its storage space (and/or available funds to purchase equipment) should be allocated to ultra-cold 324 freezers to store vaccine-H vs. refrigerators to store vaccine-L. An ultra-cold freezer may be able 325 to store a lower quantity of vaccine-H to preserve appropriate temperatures, relative to a 326 refrigerator's capacity for vaccine-L, or in order to hold the same quantity of vaccines, it may 327 take up a larger space due to its physical structure. 328

If a decision maker has the means of increasing the resource consumption ratio by either 329 reducing the resource requirements of vaccine-H relative to vaccine-L or increasing its 330 capabilities to cover more individuals with vaccine-H given the resource requirements, this is 331 always beneficial as it increases the daily number of vaccines that can be administered. However, 332

increasing the resource consumption ratio may imply different levels of complexity depending 333 on how it is defined in a given context. For example, if we refer back to the example of the ultra-334 cold freezers and refrigerators, increasing the resource consumption ratio could be very costly 335 and difficult since each ultra-cold freezer costs more than $10,000. Many hospitals, especially 336 those in rural areas, cannot afford these expensive freezers as nearly half of U.S. rural hospitals 337 have been running deficits since early 2020, stated by the chief executive of the National Rural 338

Health Association [20] . In addition, the CDC's interim COVID-19 Playbook, lastly updated on 339

October 29, 2020, also states that jurisdictions are advised not to purchase ultra-cold storage 340 equipment [21] . These scenarios would correspond to the low values of the resource 341 consumption ratios in our models, where the decision maker may not have much room to change 342 those but treat as given. In such a case, the decision maker can still minimize IAR by allocating 343 more of its available resources to the lower efficacy vaccine given its potential wider reach, 344 rather than putting a significant effort into trying to incrementally increase the resource 345 consumption ratio and allocate resources to vaccine-H. In our simulations, allocating all 346 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 resources to vaccine-H with a resource consumption ratio of 0.36 gives an IAR of 63.92%. For a 347 slightly smaller ratio of 0.34, the decision maker can still achieve an IAR lower than 63.92% 348 with a reduction in the resource allocation to vaccine-H (! $ ≤ 0.6). Hence, a decision maker can 349 still achieve the same level of IAR under a slightly higher resource consumption ratio by 350 allocating more resources to vaccine-L. This also implies that if some individuals must be 351 vaccinated early (e.g., frontline workers) but the resource consumption of vaccine-H is too high, 352 the decision maker should procure the smallest amount of vaccine-H that is enough to cover 353 those individuals, which still results in a smaller IAR than investing the entire resources into 354

vaccine-H and/or putting effort to increase the resource consumption ratio slightly. 355

We also acknowledge some limitations of this study. First, our modified SIR-D model 356

does not fully capture the potential trajectory of an infectious disease over its lifetime. There 357 could be additional stages (compartments), such as asymptomatic infected individuals who 358 spread the disease with a different transmission rate or symptomatic infected individuals who are 359 either quarantined or hospitalized such that they no longer spread the virus. Second, 360 implementation of non-pharmaceutical interventions often separates conforming individuals 361 from the susceptible population temporarily. Individuals who decide to stop conforming to the 362 interventions may re-enter the susceptible populations during a pandemic, as considered in [22] . 363 Third, a virus may mutate and change the reproduction number over time. Fourth, while we 364 assume a homogeneous population, each individual may show different characteristics to build 365 antibodies when vaccinated or to recover from the virus, depending on factors such as 366 demographics. Fifth, we model all vaccinations in an immediate deployment rather than a phased 367 rollout. Even if one receives an effective vaccine, it may still take several days to fully build 368 antibodies and fight off the infection. Lastly, our model assumes that both vaccine types require 369 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.28.21250713 doi: medRxiv preprint a single dose. Most of the current vaccine candidates against COVID-19, both mRNA-based and 370 adenovirus-vector-based, require two doses with three to four weeks apart application to provide 371 the most protection. Since the individuals who receive the first shot experience minimal 372 protection and could still get infected before the second shot, it would be worthwhile to simulate 373 a two-dose vaccine scenario. In this scenario, identifying the trade-off between the resource 374 consumption ratio and efficacy may be even more critical since the vaccines would consume 375 more resources. 376

Overall, our results suggest that allocating limited resources towards a prophylactic 377 vaccine with high efficacy that becomes available earlier than a prophylactic vaccine with lower 378 efficacy may not always result in increased benefits of a vaccine upon its implementation, 379 especially if the latter can be distributed more widely. In fact, this may result in a significant 380 deterioration in the infection attack rates if the high-efficacy vaccine is highly resource intensive, 381 relative to the low-efficacy one, such that only a few people can be vaccinated each day. 382 Therefore, identifying the resource consumption requirements of each vaccine type as a function 383 of their efficacy levels, timelines and disease characteristics, is critical for resource allocation 384 decisions, as there is a clear threshold for which vaccine type should be favored, and a significant 385 improvement in health outcomes can be achieved. Manufacturing an mRNA-based vaccine is 386 based on a new vaccine development technology, which is expected to be one of the prime 387 methods in the future. Therefore, building a suitable infrastructure for effective distribution and 388 storage of mRNA-based vaccines, considering the tradeoffs and synergies between efficacy and 389 reach, is critical. We hope that this study can provide guidance to decision makers in their 390 resource planning for different vaccine types to better prepare for future pandemics. 391 392 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 1, 2021. 5 * Under any lower resource consumption ratio, vaccine-L receives the entire allocation. † IAR under the specified resource consumption ratio (When ! " = 1, IAR is fixed at 63.51% regardless of the resource consumption ratio). ‡ Percentage of the population who become immunized with vaccine-H between days 209 and 238 (i.e., before vaccine-L becomes available) under the specified resource consumption ratio § Under any higher resource consumption ratio, vaccine-H receives the entire allocation. .00 † † Under any lower resource consumption ratio, vaccine-L receives the entire allocation. ‡ ‡ IAR under the specified resource consumption ratio § § Percentage of the population who become immunized with vaccine-H before vaccine-L becomes available under the specified resource consumption ratio *** Under any higher resource consumption ratio, vaccine-H receives the entire allocation.

Coalition for Epidemic Preparedness and Innovation. 321 vaccine candidates against 396 COVID-19 now in development

Coronavirus Vaccine Tracker

Government Engages Pfizer to 403 Produce Millions of Doses of COVID-19 Vaccine

Department of Health and Human Services. Trump Administration's Operation 407

Warp Speed Accelerates AstraZeneca COVID-19 to be Available Beginning in October

Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved 412 Success in First Interim Analysis from Phase-3 Study

AZD1222 Vaccine Met Primary Efficacy Endpoint in Preventing COVID-19

2 more vaccine developers could seek FDA's green light by February

Critical Aspects of Packaging, Storage, Preparation, and 424 Administration of mRNA and Adenovirus-vectored COVID-19 Vaccines for Optimal 425 Efficacy. Vaccine, 2020. 426 10

Vaccine Storage, Preparation, Handling Q&A

COVID-19 Vaccine: A Neutrosophic MCDM Approach for Determining 430 the Priority Groups

An interactive web-based dashboard to track COVID-19 435 in real time. The Lancet infectious diseases

The temporal association of introducing and lifting non-pharmaceutical 440 interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling 441 study across 131 countries. The Lancet Infectious Diseases

QuickFacts: Georgia

Clinical Outcomes Of A COVID-19 Vaccine: Implementation Over 448 Efficacy: Study examines how definitions and thresholds of vaccine efficacy, coupled with 449 different levels of implementation effectiveness and background epidemic severity, 450 translate into outcomes

Goldhill, O. 'We're being left behind': Rural hospitals can't afford ultra-cold freezers to 456 store the leading Covid-19 vaccine

A SIR model assumption for the spread of 464 COVID-19 in different communities